Arcadia Biosciences closed at $0.22 on Nov 12, down 6.64%, 94.2% below its 52-week closing high. Volume of 2.6M shares was 1.69× its 20-day average (above normal).
Split-adjusted performance: +10.4% over one month, -79.3% over six months, -93.9% over one year.
In the quarter ended Jun 30, 2026, revenue was $1.44M, down 0.8% from a year earlier, with a net margin of -434.2%.
Short interest was 115.6K shares at the Oct 30 settlement, down 66.3% from the prior report (4.8% of float, 1.0 days to cover).